Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 126

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 126
---
 our operations, it could
result in a material disruption of our development programs and our business operations. To the extent that any disruption or security
breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary
information, we could incur liability, our competitive position could be harmed and the further development and commercialization of product
candidates or any future product candidates could be hindered or delayed. In addition, due to limited corporate infrastructure, our entire
workforce is currently working remotely. This could increase our cyber security risk, create data accessibility concerns, and make us
more susceptible to communication disruptions.

We do not presently maintain insurance coverage to
protect against cybersecurity risks. If we procure such coverage in the future, we cannot ensure that it will be sufficient to cover any
loss we may experience as a result of such cyberattacks. Any cyber incident could have a material adverse effect on our business, financial
condition, and results of operations.

If we fail to establish and maintain proper and
effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed. 

Ensuring that we will have adequate internal financial
and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and
time-consuming effort that needs to be re-evaluated frequently. Internal control over financial reporting is a process designed to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with Generally
Accepted Accounting Principles or GAAP.

In addition, we are required to be compliant with
public company internal control requirements mandated under Section 302 and 906 of the Sarbanes-Oxley Act. If we are unable to successfully
maintain internal controls over financial reporting, the accuracy and timing of our financial reporting, and our stock price, may be adversely
affected.

 15 

Risks Related
to Our Financial Position and Need for Additional Capital 

We will need substantial additional funding. If
we are unable to secure sufficient capital in the near term, we may be required to cease operations. 

As of December 31, 2024, we had cash and cash equivalents
of $115,019 and current liabilities of $5,537,270. Since the closing date of the Reverse Merger, we have been unable to raise sufficient
capital to advance any product candidate from preclinical development into clinical development. Moreover, our existing cash resources
are not sufficient